{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:51:33Z","timestamp":1792068693365,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11302-026-10191-1","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:17:32Z","timestamp":1792066652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the P2X7 receptor in Alzheimer\u2019s disease: mechanistic insights and emerging therapeutic strategies"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-9399","authenticated-orcid":false,"given":"Maida Engels","family":"SE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7836-4314","authenticated-orcid":false,"given":"Anandhi","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"12","key":"10191_CR1","doi-asserted-by":"publisher","first-page":"e70688","DOI":"10.1002\/cns.70688","volume":"31","author":"S Ahmadi","year":"2025","unstructured":"Ahmadi S, Khaledi S, Ahmadi K, Hassanzadeh K (2025) Amyloid beta in Alzheimer\u2019s disease: mechanisms, biomarker potential, and therapeutic targets. CNS Neurosci Ther 31(12):e70688. https:\/\/doi.org\/10.1002\/cns.70688","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10191_CR2","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3390\/ijms26051935","volume":"26","author":"J Pokrzyk","year":"2025","unstructured":"Pokrzyk J, Kulczy\u0144ska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B (2025) Clinical importance of amyloid beta implication in the detection and treatment of Alzheimer\u2019s disease. Int J Mol Sci 26(5):1935. https:\/\/doi.org\/10.3390\/ijms26051935","journal-title":"Int J Mol Sci"},{"key":"10191_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060824","author":"X Hong","year":"2025","unstructured":"Hong X, Wang Y, Li W et al (2025) The role and pathogenesis of tau protein in Alzheimer\u2019s disease. Neural Regen Res. https:\/\/doi.org\/10.3390\/biom15060824","journal-title":"Neural Regen Res"},{"key":"10191_CR4","doi-asserted-by":"publisher","first-page":"106427","DOI":"10.1016\/j.nbd.2024.106427","volume":"192","author":"M Kourti","year":"2024","unstructured":"Kourti M, Metaxas A (2024) A systematic review and meta-analysis of tau phosphorylation in mouse models of familial Alzheimer\u2019s disease. Neurobiol Dis 192:106427. https:\/\/doi.org\/10.1016\/j.nbd.2024.106427","journal-title":"Neurobiol Dis"},{"key":"10191_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102927","author":"H Lei","year":"2025","unstructured":"Lei H, Chen X, Ruan L, Liu X, Ye F, Li K et al (2025) Tau post-translational modifications in Alzheimer\u2019s disease: insights into pathogenesis, therapeutic strategies, and diagnostic advances. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2025.102927","journal-title":"Ageing Res Rev"},{"key":"10191_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-025-01631-9","author":"R Ebrahimi","year":"2025","unstructured":"Ebrahimi R et al (2025) Microglial activation as a hallmark of neuroinflammation in Alzheimer\u2019s disease. Prog Neurobiol. https:\/\/doi.org\/10.1007\/s11011-025-01631-9","journal-title":"Prog Neurobiol"},{"issue":"5","key":"10191_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, van der Flier WM, Jessen F et al (2025) Neuroinflammation in Alzheimer disease. Nat Rev Immunol 25(5):321\u2013352. https:\/\/doi.org\/10.1038\/s41577-024-01104-7","journal-title":"Nat Rev Immunol"},{"key":"10191_CR8","doi-asserted-by":"publisher","unstructured":"Azmal M et al (2025) Microglial dysfunction in Alzheimer\u2019s disease: mechanisms and therapeutic implications.\u00a0https:\/\/doi.org\/10.1016\/j.expneurol.2025.115374","DOI":"10.1016\/j.expneurol.2025.115374"},{"key":"10191_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1484373","author":"S Wang","year":"2025","unstructured":"Wang S et al (2025) Mitochondrial dysfunction in Alzheimer\u2019s disease: a key pathological factor and therapeutic target. AlzheimersDement. https:\/\/doi.org\/10.3389\/fimmu.2024.1484373","journal-title":"AlzheimersDement"},{"key":"10191_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030229","author":"E Spina","year":"2025","unstructured":"Spina E et al (2025) Mitochondrial alterations, oxidative stress, and therapeutic perspectives in Alzheimer\u2019s disease. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/cells14030229","journal-title":"Antioxidants (Basel)"},{"key":"10191_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01118-y","author":"M Pszczo\u0142owska","year":"2024","unstructured":"Pszczo\u0142owska M et al (2024) Mitochondrial disorders leading to Alzheimer\u2019s disease. Ageing Res Rev. https:\/\/doi.org\/10.1007\/s11357-024-01118-y","journal-title":"Ageing Res Rev"},{"key":"10191_CR12","doi-asserted-by":"publisher","unstructured":"Liu X et al (2024) Unlocking the therapeutic potential of P2X7 receptor. https:\/\/doi.org\/10.3389\/fphar.2024.1450704","DOI":"10.3389\/fphar.2024.1450704"},{"key":"10191_CR13","doi-asserted-by":"publisher","unstructured":"Al-Aqtash R et al (2024) Ionotropic purinergic receptor 7 (P2X7) channel structure and function. https:\/\/doi.org\/10.1080\/19336950.2024.2355150","DOI":"10.1080\/19336950.2024.2355150"},{"key":"10191_CR14","doi-asserted-by":"publisher","unstructured":"Mithaiwala A et al (2025) P2RX7 dynamics in CNS disorders: molecular insights and therapeutic perspectives. https:\/\/doi.org\/10.1007\/s12035-025-05330-5","DOI":"10.1007\/s12035-025-05330-5"},{"key":"10191_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-025-04502-y","author":"M Bedetta","year":"2025","unstructured":"Bedetta M et al (2025) The multifaceted role of P2X7R in microglia and astrocytes. Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-025-04502-y","journal-title":"Neurochem Res"},{"key":"10191_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2258281","author":"YH Ahn","year":"2023","unstructured":"Ahn YH, Burnstock G, Verkhratsky A (2023) The neuroinflammatory astrocytic P2X7 receptor. Expert Opin Ther Targets. https:\/\/doi.org\/10.1080\/14728222.2023.2258281","journal-title":"Expert Opin Ther Targets"},{"key":"10191_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14496","author":"J Zhang","year":"2024","unstructured":"Zhang J et al (2024) Involvement of microglial P2X7 receptor in pain modulation. CNS Neurosci Ther. https:\/\/doi.org\/10.1111\/cns.14496","journal-title":"CNS Neurosci Ther"},{"issue":"14","key":"10191_CR18","doi-asserted-by":"publisher","first-page":"11747","DOI":"10.3390\/ijms241411747","volume":"24","author":"KE Ronning","year":"2023","unstructured":"Ronning KE et al (2023) The P2X7 receptor, a multifaceted receptor in Alzheimer\u2019s disease. Int J Mol Sci 24(14):11747. https:\/\/doi.org\/10.3390\/ijms241411747","journal-title":"Int J Mol Sci"},{"key":"10191_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/med.21952","author":"Y Yin","year":"2023","unstructured":"Yin Y et al (2023) Leveraging the ATP\u2013P2X7 receptor signalling axis to alleviate traumatic CNS damage and related complications. Med Res Rev. https:\/\/doi.org\/10.1002\/med.21952","journal-title":"Med Res Rev"},{"key":"10191_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01161-w","author":"Z Hu","year":"2023","unstructured":"Hu Z et al (2023) Role of P2X7 receptor in neurodegenerative diseases. Cell Biosci. https:\/\/doi.org\/10.1186\/s13578-023-01161-w","journal-title":"Cell Biosci"},{"key":"10191_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119646","volume":"201","author":"I Ghafir El Idrissi","year":"2026","unstructured":"Ghafir El Idrissi I, Moreira Alvarez D, Pi\u00f1a M\u00e1rquez R, Adinolfi E, Pegoraro A, Volpini R, Buccioni M, Francucci B, Pierri CL, Abate C, Leopoldo M, Brea J, Contino M, Loza MI, Lacivita E (2026) Unveiling the molecular crosstalk between the purinergic P2X7 receptor and cannabinoid subtype 2 receptor in human microglial HMC3 cells: new insights for multitarget therapies in neuroinflammation. Biomed Pharmacother 201. https:\/\/doi.org\/10.1016\/j.biopha.2026.119646","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10191_CR22","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12035-023-03699-9","volume":"61","author":"Q Huang","year":"2024","unstructured":"Huang Q, Ying J, Yu W, Dong Y, Xiong H, Zhang Y, Liu J, Wang X, Hua F (2024) P2X7 receptor: an emerging target in Alzheimer\u2019s disease. Mol Neurobiol 61(5):2866\u20132880. https:\/\/doi.org\/10.1007\/s12035-023-03699-9","journal-title":"Mol Neurobiol"},{"issue":"17","key":"10191_CR23","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/ijms21175996","volume":"21","author":"P Illes","year":"2020","unstructured":"Illes P (2020) P2X7 receptors amplify CNS damage in neurodegenerative diseases. Int J Mol Sci 21(17):5996. https:\/\/doi.org\/10.3390\/ijms21175996","journal-title":"Int J Mol Sci"},{"key":"10191_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13550-024-01103-8","volume":"14","author":"OM Alzghool","year":"2024","unstructured":"Alzghool OM, Aarnio R, Helin JS et al (2024) Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [^11C]SMW139 and [^18F]F-DPA. EJNMMI Res 14:25. https:\/\/doi.org\/10.1186\/s13550-024-01103-8","journal-title":"EJNMMI Res"},{"key":"10191_CR25","doi-asserted-by":"publisher","first-page":"102173","DOI":"10.1016\/j.pneurobio.2021.102173","volume":"208","author":"C Di Lauro","year":"2022","unstructured":"Di Lauro C, Bianchi C, Sebasti\u00e1n-Serrano \u00c1 et al (2022) P2X7 receptor blockade reduces tau induced toxicity, therapeutic implications in tauopathies. Prog Neurobiol 208:102173. https:\/\/doi.org\/10.1016\/j.pneurobio.2021.102173","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10191_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13195-025-01916-2","volume":"17","author":"CA Maschio","year":"2025","unstructured":"Maschio CA, Moreno O, Wang J et al (2025) Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer\u2019s disease brain are associated with A\u03b2, tau pathologies and synaptic loss. Alzheimers Res Ther 17(1):274. https:\/\/doi.org\/10.1186\/s13195-025-01916-2","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10191_CR27","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1021\/acschemneuro.4c00067.s001","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Cao L, Wang J et al (2024) Increased cerebral level of P2X7R in a tauopathy mouse model by PET using [^18F]GSK1482160. ACS Chem Neurosci 15(11):2112\u20132120. https:\/\/doi.org\/10.1021\/acschemneuro.4c00067.s001","journal-title":"ACS Chem Neurosci"},{"key":"10191_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fnmol.2020.00094","volume":"13","author":"L Francistiov\u00e1","year":"2020","unstructured":"Francistiov\u00e1 L, Bac\u00edkov\u00e1 A, Okr\u0161l\u00e1 Z et al (2020) The role of P2X7 receptor in Alzheimer\u2019s disease. Front Mol Neurosci 13:94","journal-title":"Front Mol Neurosci"},{"key":"10191_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107106","volume":"216","author":"KS Heavener","year":"2025","unstructured":"Heavener KS, Tamucci KA, Lee AJ et al (2025) P2RX7 modulates the function of human microglia-like cells and mediates the association of IL18 with Alzheimer\u2019s disease traits. Neurobiol Dis 216","journal-title":"Neurobiol Dis"},{"key":"10191_CR30","unstructured":"Alzheimer\u2019s Association. Medications for memory, cognition & dementia-related behaviors. Available from: Alzheimer\u2019s Association website"},{"key":"10191_CR31","doi-asserted-by":"publisher","unstructured":"Chen Y, Wang X, Zhang M et al (2024) Evaluating the efficacy and safety of Alzheimer\u2019s disease pharmacotherapies: a systematic review and meta-analysis. https:\/\/doi.org\/10.1097\/md.0000000000037799","DOI":"10.1097\/md.0000000000037799"},{"key":"10191_CR32","doi-asserted-by":"publisher","unstructured":"Thangwaritorn S et al (2024) A review of recent advances in the management of Alzheimer\u2019s disease.\u00a0https:\/\/doi.org\/10.7759\/cureus.58416","DOI":"10.7759\/cureus.58416"},{"key":"10191_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ibra.12098","author":"BC Tang","year":"2023","unstructured":"Tang BC et al (2023) Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications. Acta Pharmacol Sin. https:\/\/doi.org\/10.1002\/ibra.12098","journal-title":"Acta Pharmacol Sin"},{"key":"10191_CR34","doi-asserted-by":"publisher","unstructured":"Wu CK et al (2025) A 2025 update on treatment strategies for Alzheimer\u2019s disease. 2025. https:\/\/doi.org\/10.1097\/jcma.0000000000001252","DOI":"10.1097\/jcma.0000000000001252"},{"key":"10191_CR35","doi-asserted-by":"publisher","unstructured":"Gao Y et al (2024) Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis. https:\/\/doi.org\/10.17219\/acem\/176051","DOI":"10.17219\/acem\/176051"},{"key":"10191_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01329-7","author":"NC Fox","year":"2025","unstructured":"Fox NC, Aisen P, Cummings J et al (2025) Treatment for Alzheimer\u2019s disease. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(25)01329-7","journal-title":"Lancet"},{"key":"10191_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-03017-8","author":"W Danysz","year":"2025","unstructured":"Danysz W, Parsons CG (2025) Memantine: updates from the past decade and implications for the future. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-025-03017-8","journal-title":"J Neural Transm (Vienna)"},{"key":"10191_CR38","doi-asserted-by":"publisher","DOI":"10.12659\/msm.945091","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV (2024) A review of the current status of disease-modifying therapies and prevention of Alzheimer\u2019s disease. Med Sci Monit 30. https:\/\/doi.org\/10.12659\/msm.945091","journal-title":"Med Sci Monit"},{"key":"10191_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-025-01253-x","author":"CP Schreiber","year":"2025","unstructured":"Schreiber CP, Salloway SP (2025) Amyloid-related imaging abnormalities in the context of anti-amyloid-targeting therapies for Alzheimer\u2019s disease. Drug Saf. https:\/\/doi.org\/10.1007\/s40266-025-01253-x","journal-title":"Drug Saf"},{"key":"10191_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41398-023-02557-5","volume":"13","author":"K Recourt","year":"2023","unstructured":"Recourt K, de Boer P, Zuiker R et al (2023) Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Transl Psychiatry 13:258. https:\/\/doi.org\/10.1038\/s41398-023-02557-5","journal-title":"Transl Psychiatry"},{"key":"10191_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-024-10029-8","author":"SY Mei","year":"2024","unstructured":"Mei SY, Yang Y, Liu J et al (2024) Microglial purinergic signaling in Alzheimer\u2019s disease. Ageing Res Rev. https:\/\/doi.org\/10.1007\/s11302-024-10029-8","journal-title":"Ageing Res Rev"},{"key":"10191_CR42","doi-asserted-by":"publisher","DOI":"10.2174\/011570159x355614250130100132","author":"MC Bianchini","year":"2025","unstructured":"Bianchini MC, Franscescon F, Soares AA, Ansolin V, Pretto KP, da Cunha MLV et al (2025) Potential benefits of quercetin through P2X7 modulation against neuroinflammation in Alzheimer\u2019s disease. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/011570159x355614250130100132","journal-title":"Curr Neuropharmacol"},{"key":"10191_CR43","doi-asserted-by":"publisher","unstructured":"Natural phytochemicals as P2X7 receptor inhibitors for the treatment of inflammation-related diseases. Int J Food Sci. 2023. https:\/\/doi.org\/10.15586\/ijfs.v35i2.2288","DOI":"10.15586\/ijfs.v35i2.2288"},{"key":"10191_CR44","doi-asserted-by":"publisher","first-page":"155334","DOI":"10.1016\/j.phymed.2023.155334","volume":"128","author":"Z Liu","year":"2024","unstructured":"Liu Z, Liu W, Han M, Wang M, Li Y, Yao Y et al (2024) A comprehensive review of natural product-derived compounds acting on P2X7R: the promising therapeutic drugs in disorders. Phytomedicine 128:155334. https:\/\/doi.org\/10.1016\/j.phymed.2023.155334","journal-title":"Phytomedicine"},{"issue":"11","key":"10191_CR45","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2174\/0929867330666230403094538","volume":"31","author":"I Ghafir El Idrissi","year":"2024","unstructured":"Ghafir El Idrissi I, Podlewska S, Abate C, Bojarski AJ, Lacivita E, Leopoldo M (2024) Structure-activity relationships and therapeutic potential of purinergic P2X7 receptor antagonists. Curr Med Chem 31(11):1361\u20131403. https:\/\/doi.org\/10.2174\/0929867330666230403094538","journal-title":"Curr Med Chem"},{"key":"10191_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05417-z","author":"U Kochman","year":"2025","unstructured":"Kochman U et al (2025) Targeted nanoparticles for drug delivery across the blood-brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Pharmaceutics. https:\/\/doi.org\/10.1007\/s12035-025-05417-z","journal-title":"Pharmaceutics"},{"key":"10191_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.107966","author":"EA Elmorsy","year":"2025","unstructured":"Elmorsy EA et al (2025) Targeted intranasal brain delivery of brilliant blue G via chitosan-coated spanlastic nanovesicles for Alzheimer\u2019s disease. Eur J Pharm Sci. https:\/\/doi.org\/10.1016\/j.jddst.2025.107966","journal-title":"Eur J Pharm Sci"},{"key":"10191_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1591438","author":"K Wang","year":"2025","unstructured":"Wang K et al (2025) Nanocarrier-based targeted drug delivery for Alzheimer\u2019s disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2025.1591438","journal-title":"Front Pharmacol"},{"key":"10191_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1405423","author":"CE Muolokwu","year":"2024","unstructured":"Muolokwu CE et al (2024) Functionalized nanoparticles to deliver nucleic acids to the brain in Alzheimer\u2019s disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1405423","journal-title":"Front Pharmacol"},{"key":"10191_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00393-7","author":"HM Gebril","year":"2024","unstructured":"Gebril HM et al (2024) Nanotechnology for microglial targeting and inhibition of Alzheimer\u2019s disease progression. Fluids Barriers CNS. https:\/\/doi.org\/10.1186\/s40035-023-00393-7","journal-title":"Fluids Barriers CNS"},{"issue":"8","key":"10191_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","volume":"38","author":"JL Cummings","year":"2024","unstructured":"Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J (2024) Alzheimer\u2019s disease: combination therapies and clinical trials for combination therapy development. CNS Drugs 38(8):613\u2013624. https:\/\/doi.org\/10.1007\/s40263-024-01103-1","journal-title":"CNS Drugs"},{"key":"10191_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/med.22045","author":"P Mayo","year":"2024","unstructured":"Mayo P et al (2024) Innovative pathological network-based multitarget drug development in Alzheimer\u2019s disease. ACS Chem Neurosci. https:\/\/doi.org\/10.1002\/med.22045","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"10191_CR53","doi-asserted-by":"publisher","first-page":"e70022","DOI":"10.1002\/trc2.70022","volume":"10","author":"JP Hl\u00e1vka","year":"2024","unstructured":"Hl\u00e1vka JP, Kinoshita AT, Jeyasingh D, Huang C, Mirsafian L, Jacobson M (2024) Emerging Alzheimer\u2019s disease treatment paradigms: a late-stage clinical trial review. Alzheimers Dement (N Y) 10(4):e70022. https:\/\/doi.org\/10.1002\/trc2.70022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10191_CR54","doi-asserted-by":"publisher","unstructured":"Naimi N et al (2024) Advanced nanoparticle strategies for optimizing RNA therapeutics in neurodegenerative diseases. https:\/\/doi.org\/10.1016\/j.biopha.2024.116691","DOI":"10.1016\/j.biopha.2024.116691"},{"issue":"21","key":"10191_CR55","doi-asserted-by":"publisher","first-page":"10265","DOI":"10.3390\/ijms262110265","volume":"26","author":"JSY Cheah","year":"2025","unstructured":"Cheah JSY, Bartlett R, Schwarz N, Sluyter R (2025) Genetic variations in the P2X7 receptor: opportunities and challenges for drug development. Int J Mol Sci 26(21):10265. https:\/\/doi.org\/10.3390\/ijms262110265","journal-title":"Int J Mol Sci"},{"key":"10191_CR56","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1038\/s41467-025-65847-0","volume":"16","author":"CR Guo","year":"2025","unstructured":"Guo CR, Cao P, Hattori M, Liu H, Yu Y et al (2025) Understanding interspecies drug response variations between human and rodent P2X7 receptors. Nat Commun 16:10827. https:\/\/doi.org\/10.1038\/s41467-025-65847-0","journal-title":"Nat Commun"},{"issue":"16","key":"10191_CR57","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3390\/jcm13164661","volume":"13","author":"A Bougea","year":"2024","unstructured":"Bougea A, Gourzis P, Spantideas N, Galanis P, Papadimitriou A, Daskalopoulou A et al (2024) Biomarker-based precision therapy for Alzheimer\u2019s disease: multidimensional evidence leading a new breakthrough in personalized medicine. J Clin Med 13(16):4661. https:\/\/doi.org\/10.3390\/jcm13164661","journal-title":"J Clin Med"},{"issue":"3","key":"10191_CR58","doi-asserted-by":"publisher","first-page":"100107","DOI":"10.1016\/j.neumar.2025.100107","volume":"2","author":"J Braudeau","year":"2025","unstructured":"Braudeau J, Souchet B, Streel E, Claeysen S, B\u00e9gou M (2025) Optimizing Alzheimer\u2019s diagnosis and precision medicine: a narrative review unlocking the potential of multiomics markers. NeuroMarkers 2(3):100107. https:\/\/doi.org\/10.1016\/j.neumar.2025.100107","journal-title":"NeuroMarkers"},{"key":"10191_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/brx2.55","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Bi L, Huang G, Li Z, Wei H, Li G et al (2024) Positron emission tomography imaging of the P2X7 receptor with a novel tracer, [18F]GSK1482160, in a transgenic mouse model of Alzheimer\u2019s disease and healthy non-human primates. Brain Behav. https:\/\/doi.org\/10.1002\/brx2.55","journal-title":"Brain Behav"},{"key":"10191_CR60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbi.2023.09.011","volume":"114","author":"P Beltran-Lobo","year":"2023","unstructured":"Beltran-Lobo P, Hughes MM, Troakes C, Croft CL, Rupawala H, Jutzi D et al (2023) P2X7R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes. Brain Behav Immun 114:414\u2013429. https:\/\/doi.org\/10.1016\/j.bbi.2023.09.011","journal-title":"Brain Behav Immun"},{"key":"10191_CR61","doi-asserted-by":"publisher","unstructured":"Ghafir El Idrissi I, Spinaci A, Vitone D, Intranuovo F, Niso M, Brunetti L, Francucci B, Pazarlar BA, Magnusdottir KH, Paradies E, Marobbio CM (2026) A holistic approach to identifying a positron emission tomography (PET) tracer candidate for in vivo imaging of purinergic P2X7 receptor in neuroinflammation. ACS Pharmacology & Translational Science 9(4):997\u20131009. https:\/\/doi.org\/10.1021\/acsptsci.5c00820.s001","DOI":"10.1021\/acsptsci.5c00820.s001"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10191-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:17:34Z","timestamp":1792066654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10191-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10191"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10191-1","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable. This article is a review of previously published literature and does not involve human participants, animals, or identifiable human data.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT to assist with language refinement and manuscript organization and figure preparation. The authors reviewed and edited all content and take full responsibility for the final manuscript.","order":4,"name":"Ethics","label":"Declaration of generative AI use","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This manuscript has not been previously posted as a preprint.","order":5,"name":"Ethics","label":"Preprint","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"79"}}